Get started
Author

Luis Wehbe

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
2021 · Joseph K Han, Claus Bachert, et al. · The Lancet Respiratory Medicine · 629
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD
2014 · Andrea Rossi, Thys van der Molen, et al. · European Respiratory Journal · 122
PDF
Pamrevlumab for Idiopathic Pulmonary Fibrosis
2024 · Ganesh Raghu, Luca Richeldi, et al. · JAMA · 80
Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial
2018 · Pablo Altman, Luis Wehbe, et al. · BMC Pulmonary Medicine · 70
PDF
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
2021 · Gerald J. Gleich, Florence Roufosse, et al. · The Journal of Allergy and Clinical Immunology In Practice · 46
PDF
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
2023 · Teresa H. Evering, Kara W. Chew, et al. · Annals of Internal Medicine · 32
PDF
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
2022 · Marc E. Rothenberg, Florence Roufosse, et al. · The Journal of Allergy and Clinical Immunology In Practice · 23
PDF
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
2026 · Alberto Papi, Neil J Greening, et al. · The Lancet · 20
Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study
2023 · Wytske Fokkens, Andrew Trigg, et al. · Journal of Patient-Reported Outcomes · 18
PDF
Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre‐quit and post‐quit periods
2018 · Dunja Przulj, Luis Wehbe, et al. · Addiction · 14
Want, need and habit as drivers of smoking behaviour: A preliminary analysis
2017 · Luis Wehbe, Harveen Kaur Ubhi, et al. · Addictive Behaviors · 8
PDF
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial
2026 · Justin M Oldham, Arata Azuma, et al. · American Journal of Respiratory and Critical Care Medicine · 7
[Chronic eosinophilic pneumonia].
2012 · F Vivero, C Ciocchini, et al. · PubMed · 4
Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial
2026 · Toby M Maher, Mark J Hamblin, et al. · American Journal of Respiratory and Critical Care Medicine · 3
Association of long COVID with health-related quality-of-life outcomes
2026 · Malini M. Gandhi, Carlee Moser, et al. · Scientific Reports · 2
PDF
P288 Copd patients with varying severity of airflow limitation achieve highest peak inspiratory flow rate via the breezhaler® inhaler compared to the ellipta® or the handihaler® dry powder inhalers
2016 · P Goyal, L Wehbe, et al. · Thorax · 1
PDF
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
2015 · Andrea Rossi, Thys Van der Molen, et al. · 1
Salmeterol/fluticasone combination instead of indacaterol orvice-versa?
2015 · Andrea Rossi, Thys van der Molen, et al. · European Respiratory Journal · 1
PDF
Neumonía eosinofílica crónica. informe de caso
2012 · Florencia Vivero, Cleto Ciocchini, et al. · Revista de la Facultad de Ciencias Médicas de Córdoba · 1
Association of long COVID with health-related quality-of-life outcomes
2026 · Gelman, Michael, Moyano, Susana, et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)
PDF
Increasing the dose of nicotine replacement treatment to individual needs
2017 · Dunja Przulj, Luis Wehbe · http://isrctn.com/
Antioxidant Capacity in Copd, Smokers and Asthmatic Plasma
1994 · I Rahman, LA Wehbe, et al. · Clinical Science
Works count: 27
Citation count: 1,080
H-index: 10
I10-index: 10
Year
Topic
Type